[ad_1]
Drugmaker Eli Lilly continues to struggle to meet demand for its type 2 diabetes drug Munjaro.
Munjaro, a well-known brand for the drug tirzepatide, has become popular alongside fellow diabetes drug Ozempic (semaglutide) in recent years, as celebrities, influencers, and ordinary people alike have started using both off-label drugs for weight loss. Masu. Eli Lilly then received FDA approval for her Zepbound, a version of tirzepatide used specifically for weight loss rather than diabetes management.
Novo Nordisk, the maker of Ozempic, also has a version of semaglutide, called Wigovy, approved for weight loss, separate from its diabetes drug.
Despite the availability of these alternatives intended for use in weight management, people with diabetes face ongoing problems securing the drugs they need due to increased demand. In many cases, if you are not diagnosed with diabetes and use these medications solely for weight loss, insurance will not cover them, so many people continue to use their original off-label medications.
According to the company and the FDA, people who rely on Mounjaro are currently facing shortages and backorders, and that situation is likely to continue for the foreseeable future. Click here for the latest information on Mounjaro stock and availability.
Munjaro shortage and inventory update
According to the U.S. Food and Drug Administration, as of the latest update on March 5, tirzepatide injections are “currently in short supply.” Eli Lilly regularly reports and verifies the availability of its medicines on the FDA Drug Shortage List and has continued to do so since the shortage report was issued in December 2022.
As of early March, only certain Munjaro injection doses are currently in short supply. Everything listed as having limited availability will remain in place until March 2024. This includes:
- Munjaro, injection, 10 mg/.5 mL (NDC 0002-1471-80)
- Munjaro, Injection, 12.5 mg/.5 mL (NDC 0002-1460-80)
- Munjaro, injection, 15 mg/.5 mL (NDC 0002-1457-80)
All three drugs on the list say the reason for the stock disruption is “increased demand for the drug.”
Other doses that were previously in short supply will now be available in March, including 5 mg/0.5 mL, 2.5 mg/0.5 mL, and 7.5 mg/0.5 mL Mounjaro Injection.
Is Munjaro on backorder?
According to a statement from Eli Lilly to USA TODAY, the manufacturer expects intermittent backorders to continue for certain doses of Munjaro. In March, the above doses may be on backorder at retailers nationwide.
People using tirzepatide for weight loss rather than diabetes management can order full doses of Zepbound wholesale at pharmacies across the United States.
When will Munjaro be restocked?
Eli Lilly referred USA TODAY to the FDA’s drug shortage website to monitor and provide up-to-date information on the availability of its medicines. They regularly release drugs that are on backorder at the time of manufacture.
“Lilly expects to experience intermittent backorders for certain doses of Munjaro as over-dose patient demand remains dynamic,” the company said in a statement. “We recognize that this situation can cause disruption to people’s treatment plans and are working urgently to address this.”
The company went on to say it continues to “invest and add to manufacturing and supply capacity around the world.”
“Additional manufacturing facilities in North Carolina, combined with additional initiatives and expansions at other locations, will allow us to significantly expand our manufacturing over the next several years,” said Eli Lilly.
Eli Lilly cracks down on people using Munjaro for celebrity and ‘look’ purposes
Eli Lilly said it was considering cracking down on people who had access to its medicines, particularly Mr. Munjaro. The company released the commercial on February 23, ahead of the Academy Awards ceremony. The ad is set against the backdrop of a celebrity awards ceremony.
“Some people are using drugs for which they were not intended,” the narrator says. “In a smaller dress or tuxedo. For the big night. To look good. But that’s not the point. People whose health is affected by obesity are why we work on these drugs. Who It’s important to get it.”
Eli Lilly CEO David Ricks later told CNN that the drug was developed for people with health issues and not “to make celebrities look a little better.” He said no.
“We are still a long way from being able to supply these drugs to the billion obese patients, let alone those who want to lose weight for cosmetic reasons,” he told the outlet. “So we need to prioritize and that’s what this ad is about, giving priority to those who need it most.”
“Let’s think about it seriously”:Eli Lilly slams Hollywood’s obsession with Ozempic ahead of Oscars
[ad_2]
Source link
